Insights

The now-urgent automation agenda: out-of-control regulatory workloads necessitate AI adoption

A new independent survey of senior US pharma regulatory professionals suggests that commitment to AI investment is much higher than might be expected, although...

Improving life science R&D outcomes with AI

Maximizing the potential AI/data-driven model of drug discovery requires the technology’s full integration into R&D. Biorelate’s Dr Ben Sidders explains. Pharma R&D latest disruption is...

The medical device sector’s surging regulatory burden: how are suppliers coping?

Regulators around the world are increasing their scrutiny of medical devices as these become more critical to patient outcomes. Referencing new research, Peter Muller...

The Future of Gene Therapies: Three Trends

“Maps don’t show you where you will go in life, they show you where you might go.”—John Green Over...

A Patient Centric Approach to Clinical Research is Key for Product Development

Ensuring a patient centric approach during clinical research is vitally important to research sponsors and their partners. A clinical research site that...

The FDA and AAV-Based Gene Therapy Safety: What You Should Know

Science fiction author Arthur C. Clarke once commented that “Any sufficiently advanced technology is indistinguishable from magic.” Over the last couple of...

Patient Engagement – What History Teaches Us About Pharma’s Future Evolution

The pharmaceutical industry continues to grow by leaps and bounds. Advancements are happening on a weekly basis. But every time we take...

Monoclonal Antibodies Offer Much Needed Protection for the Immunocompromised Population

Even though we don’t feel it or notice it, each minute, our bodies’ immune systems are hard at work eliminating abnormal cells,...

Latest news

Merck Signs $493M Agreement to Use Cyprumed’s Oral Peptide Platform

Merck & Co. is taking a significant step toward transforming its peptide therapies into convenient oral tablets through a...

The late-stage research of Bristol Myers’ heart disease medication falls short of its primary objectives

Bristol Myers Squibb disclosed that its drug stavartanate did not successfully improve functional capacity or symptom intensities in heart...

J&J MedTech presents the first Ottava surgical robot clinical cases

Johnson & Johnson MedTech successfully conducted the initial clinical use of Ottava surgical robot through a minimally invasive gastric...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you

Ultragenyx and Mereo’s Genetic Treatment Slashes Bone Fractures by almost 70%

In a significant breakthrough, Ultragenyx and Mereo's...

Galactico Discontinues Lung Fibrosis Work Following Phase 2 Failure

Midstage results indicated that Galecto's inhalation treatment...

Xeris Pharmaceuticals gets stockholder nod on Strongbridge Biopharma acquisition

The shareholders of Xeris Pharmaceuticals, on 15th...